Astrazeneca Pharma India & Dr Reddys Laboratories enter into distribution agreement

Astrazeneca Pharma India and Dr Reddys Laboratories announced that they have entered into a distribution agreement for Riax, a new brand of saxagliptin and Riax-M a fixed dose combination of saxagliptin with metformin. Both Riax and Riax M are trademarks of the AstraZeneca group. AZPIL already has two brands under the trademark Onglyza and Kombiglyze for saxagliptin and in fixed dose combination with metformin respectively, promoted and distributed in the Indian market.

Powered by Capital Market - Live News